Extends Projected Cash Runway through Q3 2019 to Focus on Clinical-Stage Programs and Immuno-Oncology Discovery and Development
REDWOOD CITY, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, announced today a significant reduction in its workforce to focus internal efforts on the advancement of three clinical-stage programs to key milestones and continued immuno-oncology drug discovery and development, while seeking to partner select pipeline assets.
OncoMed will reduce its workforce by approximately 50 percent, resulting in 64 remaining full-time employees. Through implementation of the plan announced today, OncoMed expects to realize significant cost savings of approximately $60 million over the next two years associated with personnel and operating expenses. The company anticipates having sufficient cash to fund operations through Q3 2019, excluding any revenue generated from existing partnerships or potential new partnering arrangements.
Read More: http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1022595
REDWOOD CITY, Calif., April 17, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported top-line results from the company's randomized 145-patient Phase 2 PINNACLE clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) in combination with etoposide plus either cisplatin or carboplatin chemotherapy ("chemotherapy") in previously untreated patients with extensive-stage small cell lung cancer. Results for the combination of tarextumab plus chemotherapy were undifferentiated from those of chemotherapy plus placebo, and therefore the trial did not meet its primary endpoint of progression-free survival or secondary endpoints of overall survival and biomarkers reflective of Notch pathway gene activation.
Via: MedPage Today
Complex aortic arch configurations and internal carotid artery (ICA) tortuosity were bad news for carotid artery stenting, but not endarterectomy, according to an MRI substudy of the International Carotid Stenting Study (ICSS).
Via: Hattiesburg American
Forrest General Hospital became the first hospital in Mississippi to use the transcarotid artery revascularization method of carotid stenting on Feb. 27.
Via: Albuquerque Journal
ALBUQUERQUE, N.M. — Dudley Sue Bock, 75, received the shocking news last July that she had a 70 percent blockage in one of the two arteries that provide blood to her brain.
OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017
Anti-TIGIT Demonstrates Potent Anti-Tumor Activity in Preclinical Models
Via: Yahoo! Finance
Outset Medical, a commercial-stage company delivering new technology into the $13 billion global dialysis market, today announced the appointment of Gus Castello as the company’s chief operating officer.
Via: The Hill
BY SEAN DUFFY, OPINION CONTRIBUTOR
OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem cell therapeutic candidates in a total of six presentations at the upcoming American Association for Cancer Research (AACR) Meeting to be held April 1-5, 2017 in Washington, DC.
Via: ASN Kidney News
An interview with Leslie Trigg, President and CEO of Outset Medical